[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100474850":3},{"organization":4,"armGroups":7,"interventions":18,"overallOfficials":25,"centralContacts":30,"locations":37,"responsibleParty":227,"collaborators":24,"id":229,"slug":230,"hasResults":231,"nctId":232,"briefTitle":233,"officialTitle":234,"acronym":24,"eligibilityCriteria":235,"healthyVolunteers":231,"sex":236,"minAge":237,"maxAge":24,"enrollmentInfo":238,"targetDuration":24,"studyType":241,"phases":242,"briefSummary":245,"conditions":246,"keywords":24,"overallStatus":40,"whyStopped":24,"lastUpdateSubmitDate":249,"lastUpdatePostDateStruct":250,"startDateStruct":253,"completionDateStruct":255,"leadSponsor":257,"locationsCount":258},{"fullName":5,"class":6},"Step Pharma, SAS","INDUSTRY",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Phase 1 (Part 1, Dose Escalation)","EXPERIMENTAL","Up to 5 dose levels with STP938 administered as oral monotherapy",[13],"Drug: STP938",{"label":15,"type":10,"description":16,"interventionNames":17},"Phase 2 (Part 2; expansion)","At defined dose level(s) with STP938 administered as oral monotherapy",[13],[19],{"type":20,"name":21,"description":22,"armGroupLabels":23,"otherNames":24},"DRUG","STP938","Small molecule",[9,15],null,[26],{"name":27,"affiliation":28,"role":29},"Maureen Higgins","Step Pharma","STUDY_DIRECTOR",[31,35],{"name":27,"role":32,"phone":33,"phoneExt":24,"email":34},"CONTACT","+33 1 86 26 43 56","STP938-101@step-ph.com",{"name":36,"role":32,"phone":33,"phoneExt":24,"email":34},"Duc Tran",[38,55,68,83,99,110,124,135,146,159,171,182,193,204,215],{"facility":39,"status":40,"city":41,"state":42,"zip":43,"country":44,"countryCode":45,"cosmosGeoPoint":46,"geoPoint":51,"contacts":52},"Colorado Blood Cancer Institute","RECRUITING","Denver","Colorado","80218","United States","US",{"type":47,"coordinates":48},"Point",[49,50],-104.9847,39.73915,{"lat":50,"lon":49},[53],{"name":54,"role":32,"phone":24,"phoneExt":24,"email":24},"M Tees",{"facility":56,"status":40,"city":57,"state":58,"zip":59,"country":44,"countryCode":45,"cosmosGeoPoint":60,"geoPoint":64,"contacts":65},"Florida Cancer Specialists","Sarasota","Florida","34232",{"type":47,"coordinates":61},[62,63],-82.53065,27.33643,{"lat":63,"lon":62},[66],{"name":67,"role":32,"phone":24,"phoneExt":24,"email":24},"M Patel",{"facility":69,"status":40,"city":70,"state":70,"zip":71,"country":44,"countryCode":45,"cosmosGeoPoint":72,"geoPoint":76,"contacts":77},"Memorial Sloan Kettering","New York","10065",{"type":47,"coordinates":73},[74,75],-74.00597,40.71427,{"lat":75,"lon":74},[78,81],{"name":79,"role":32,"phone":80,"phoneExt":24,"email":24},"Robert Stuver","646-608-4308",{"name":79,"role":82,"phone":24,"phoneExt":24,"email":24},"PRINCIPAL_INVESTIGATOR",{"facility":84,"status":40,"city":85,"state":85,"zip":86,"country":87,"countryCode":88,"cosmosGeoPoint":89,"geoPoint":93,"contacts":94},"Hôpital Saint-Louis","Paris","75610","France","FR",{"type":47,"coordinates":90},[91,92],2.3488,48.85341,{"lat":92,"lon":91},[95,97],{"name":96,"role":32,"phone":24,"phoneExt":24,"email":24},"Halim Bataouche",{"name":98,"role":82,"phone":24,"phoneExt":24,"email":24},"Adèle de Masson",{"facility":100,"status":40,"city":101,"state":24,"zip":24,"country":87,"countryCode":88,"cosmosGeoPoint":102,"geoPoint":106,"contacts":107},"The Centre Léon Bérard","Lyon",{"type":47,"coordinates":103},[104,105],4.84789,45.74906,{"lat":105,"lon":104},[108],{"name":109,"role":32,"phone":24,"phoneExt":24,"email":24},"Yann Guillerman",{"facility":111,"status":40,"city":112,"state":24,"zip":24,"country":87,"countryCode":88,"cosmosGeoPoint":113,"geoPoint":117,"contacts":118},"Institut Paoli Calmettes","Marseille",{"type":47,"coordinates":114},[115,116],5.38107,43.29695,{"lat":116,"lon":115},[119,122],{"name":120,"role":32,"phone":121,"phoneExt":24,"email":24},"Jean Laurent L'Attention",": +33 (0)4 9122 37 29",{"name":123,"role":82,"phone":24,"phoneExt":24,"email":24},"Robin Noel",{"facility":125,"status":40,"city":126,"state":24,"zip":24,"country":87,"countryCode":88,"cosmosGeoPoint":127,"geoPoint":131,"contacts":132},"CHU de Nantes","Nantes",{"type":47,"coordinates":128},[129,130],-1.55336,47.21725,{"lat":130,"lon":129},[133],{"name":134,"role":32,"phone":24,"phoneExt":24,"email":24},"Benoit Tessoulin",{"facility":136,"status":40,"city":137,"state":24,"zip":24,"country":87,"countryCode":88,"cosmosGeoPoint":138,"geoPoint":142,"contacts":143},"Institut Gustave Roussy","Villejuif",{"type":47,"coordinates":139},[140,141],2.35992,48.7939,{"lat":141,"lon":140},[144],{"name":145,"role":32,"phone":24,"phoneExt":24,"email":24},"Vincent Ribrag",{"facility":147,"status":40,"city":148,"state":24,"zip":24,"country":149,"countryCode":150,"cosmosGeoPoint":151,"geoPoint":155,"contacts":156},"University Hospitals of Leicester NHS Trust","Leicester","United Kingdom","UK",{"type":47,"coordinates":152},[153,154],-1.13169,52.6386,{"lat":154,"lon":153},[157],{"name":158,"role":32,"phone":24,"phoneExt":24,"email":24},"Matthew Ahearne",{"facility":160,"status":40,"city":161,"state":24,"zip":24,"country":149,"countryCode":150,"cosmosGeoPoint":162,"geoPoint":166,"contacts":167},"Imperial College \u002F Clinical Trials Unit, Hammersmith Hospital","London",{"type":47,"coordinates":163},[164,165],-0.12574,51.50853,{"lat":165,"lon":164},[168],{"name":169,"role":32,"phone":170,"phoneExt":24,"email":24},"Lucy Cook","0203 313 4340",{"facility":172,"status":40,"city":173,"state":24,"zip":24,"country":149,"countryCode":150,"cosmosGeoPoint":174,"geoPoint":178,"contacts":179},"The Christie","Manchester",{"type":47,"coordinates":175},[176,177],-2.23743,53.48095,{"lat":177,"lon":176},[180],{"name":181,"role":32,"phone":24,"phoneExt":24,"email":24},"Kim Linton",{"facility":183,"status":40,"city":184,"state":24,"zip":24,"country":149,"countryCode":150,"cosmosGeoPoint":185,"geoPoint":189,"contacts":190},"Nottingham City Hospital","Nottingham",{"type":47,"coordinates":186},[187,188],-1.15047,52.9536,{"lat":188,"lon":187},[191],{"name":192,"role":32,"phone":24,"phoneExt":24,"email":24},"Chris Fox",{"facility":194,"status":40,"city":195,"state":24,"zip":24,"country":149,"countryCode":150,"cosmosGeoPoint":196,"geoPoint":200,"contacts":201},"Churchill Hospital","Oxford",{"type":47,"coordinates":197},[198,199],-1.25596,51.75222,{"lat":199,"lon":198},[202],{"name":203,"role":32,"phone":24,"phoneExt":24,"email":24},"Graham Collins",{"facility":205,"status":40,"city":206,"state":24,"zip":24,"country":149,"countryCode":150,"cosmosGeoPoint":207,"geoPoint":211,"contacts":212},"Derriford Hospital","Plymouth",{"type":47,"coordinates":208},[209,210],-4.14305,50.37153,{"lat":210,"lon":209},[213],{"name":214,"role":32,"phone":24,"phoneExt":24,"email":24},"David Lewis",{"facility":216,"status":40,"city":217,"state":24,"zip":24,"country":149,"countryCode":150,"cosmosGeoPoint":218,"geoPoint":222,"contacts":223},"The Royal Marsden","Sutton",{"type":47,"coordinates":219},[220,221],-0.2,51.35,{"lat":221,"lon":220},[224],{"name":225,"role":32,"phone":24,"phoneExt":24,"email":226},"Dima El Sharkawi","HaemOncGT@rmh.nhs.uk",{"type":228,"investigatorFullName":24,"investigatorTitle":24,"investigatorAffiliation":24,"oldNameTitle":24,"oldOrganization":24},"SPONSOR","100474850","phase-1-a-phase-12-study-of-stp938-dencatistat-for-adult-subjects-with-relapsedrefractory-b-cell-and-t-cell-lymphomas-100474850",false,"NCT05463263","A Phase 1\u002F2 Study of STP938 (Dencatistat) for Adult Subjects With Relapsed\u002FRefractory B-Cell and T-Cell Lymphomas","An Open-Label, First in Human, Phase 1\u002F2 to Evaluate Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of the CTPS1 Inhibitor STP938 In Adult Subjects With Relapsed\u002FRefractory B-Cell and T-Cell Lymphomas","Main Inclusion Criteria:\n\n* Signed and dated informed consent, and able to comply with the study procedures and any locally required authorization.\n* Male or female aged ≥ 18 years.\n* Relapsed\u002Frefractory patients with histologically confirmed diagnosis of B cell or T cell lymphoma\n* Must have received at least 2 prior systemic therapies and have no treatment options known to provide clinical benefit\n* Must have measurable disease per Lugano lymphoma classification except for cutaneous T-cell lymphoma (CTCL) which is measured via International Society for Cutaneous Lymphomas (ISCL)\u002F European Organization of Research and Treatment of Cancer (EORTC).\n* Eastern Cooperative Oncology Group (ECOG) performance status ≤2.\n* Life expectancy \\> 3 months as assessed by the Investigator.\n* Adequate organ function (bone marrow, hepatic, renal function and coagulation).\n* All toxicities (except alopecia) from prior cancer treatments or procedures must have resolved to ≤Grade 1 or returned to baseline levels prior to enrollment.\n\nMain Exclusion Criteria:\n\n* Pregnant or breastfeeding females and women of child bearing potential or males unwilling to comply with contraception requirements.\n* Known carcinomatous meningitis or central nervous system (CNS) involvement with lymphoma.\n* Active malignancy within 2 years of study enrollment\n* Prior radiation or surgical resection of their lymphoma without additional sites of measurable disease outside of the radiation field or subjects who have received prior radiation or surgical resection of their lymphoma ≤2 weeks prior to the first dose of study drug.\n* Systemic cancer treatments, monoclonal antibody-directed therapies, other investigational agents within 4 weeks before enrollment, or \\\u003C5 half-lives since completion of previous investigational therapy, whichever is shorter.\n* Uncontrolled intercurrent illness.\n* Immunocompromised subjects with increased risk of opportunistic infections or history of opportunistic infection in the last 12 months.\n* Known active or chronic hepatitis B or active hepatitis C virus (HCV) infection.\n* Subjects who have received a live vaccine within 30 days prior to study enrollment or whilst participating in the study.\n* Subjects with corrected QT interval \\>470 msec based on averaged triplicate electrocardiogram (ECG) readings at the Screening Visit using the QT interval corrected for heart rate using Fridericia's method (QTcF).\n* Subjects who received a severe acute respiratory syndrome coronavirus 2 vaccine ≤3 weeks prior to study drug dosing.","ALL","18 Years",{"count":239,"type":240},180,"ESTIMATED","INTERVENTIONAL",[243,244],"PHASE1","PHASE2","The Phase 1 part of the study is a dose escalation of STP938 as monotherapy.\n\nThe Phase 2 part of the study is cohort expansion of STP938 as a monotherapy in 5 different B and T cell lymphomas.",[247,248],"Lymphoma, B-Cell","Lymphoma, T-Cell","2026-06-13",{"date":251,"type":252},"2026-06-16","ACTUAL",{"date":254,"type":252},"2022-08-03",{"date":256,"type":240},"2026-12",{"name":5,"class":6},15]